Daiichi’s Edoxaban Steps Up As Once-Daily Competitor To Xarelto
This article was originally published in The Pink Sheet Daily
Daiichi Sankyo plans to file two once-daily doses of the edoxaban for stroke prevention in atrial fibrillation, but the lowest one was associated with more ischemic strokes compared to warfarin in the ENGAGE AF-TIMI 48 study, which could limit prospects for use.
You may also be interested in...
FDA clinical reviewers recommend approval of the Factor Xa inhibitor only for patients with renal impairment because of adverse efficacy results in patients with normal kidney function; at an Oct. 30 meeting, the cardio-renal advisory committee also will be asked to consider approval at a higher, untested dose.
J&J and Bayer continue quest for acute coronary syndrome claim following three rejections by FDA; this time, Xarelto will be tested on top of only one antiplatelet drug instead of two.
A research agreement between AstraZeneca and Germany’s Max Planck Institute and a development pact between Portola and Daiichi Sankyo for an adverse-bleeding therapy highlight the week’s deal-making. In addition, HealthCare Royalty Partners announced a new royalty deal with Supernus and reworked its 2012 loan with Raptor, while GlobeImmune went public on its second IPO attempt.